Zhang J, Simpson C, Berner J, et al. Systematic identification of anticancer drug targets reveals a nucleus-to-mitochondria ROS-sensing pathway. Cell. 2023;186(11):2361-2379.e25. doi:10.1016/j.cell.2023.04.026
Chemical Biology and Therapeutics Science Program
Lim D, Zhou Q, Cox KJ, et al. A general approach to identify cell-permeable and synthetic anti-CRISPR small molecules. Nat Cell Biol. 2022. doi:10.1038/s41556-022-01005-8
Small JC, Joblin-Mills A, Carbone K, et al. Phenotypic Screening for Small Molecules that Protect β-Cells from Glucolipotoxicity. ACS Chem Biol. 2022. doi:10.1021/acschembio.2c00052
Yamada K, Deb A, Shoba VM, et al. Rational Design of Silicon-Based Zinc Ionophores. Angew Chem Int Ed Engl. 2022:e202201698. doi:10.1002/anie.202201698
Shoba VM, Godage DNPM, Chaudhary SK, Deb A, Siriwardena SU, Choudhary A. Synthetic Reprogramming of Kinases Expands Cellular Activities of Proteins. Angewandte Chemie (International ed. in English). 2022;61(29):e202202770. doi:10.1002/anie.202202770
Sheriff A, Guri I, Zebrowska P, et al. ABE8e adenine base editor precisely and efficiently corrects a recurrent COL7A1 nonsense mutation. Scientific reports. 2022;12(1):19643. doi:10.1038/s41598-022-24184-8
Modell AE, Lim D, Nguyen TM, Sreekanth V, Choudhary A. CRISPR-based therapeutics: current challenges and future applications. Trends in pharmacological sciences. 2022;43(2):151-161. doi:10.1016/j.tips.2021.10.012
Siegenfeld AP, Roseman S, Roh H, et al. Polycomb-lamina antagonism partitions heterochromatin at the nuclear periphery. Nature communications. 2022;13(1):4199. doi:10.1038/s41467-022-31857-5
Ngan K. CRISPR-Suppressor Scanning for Systematic Discovery of Drug-Resistance Mutations. Current protocols. 2022;2(12):e614. doi:10.1002/cpz1.614
Gosavi P, Ngan K, Yeo M, et al. Profiling the Landscape of Drug Resistance Mutations in Neosubstrates to Molecular Glue Degraders. ACS central science. 2022;8(4):417-429. doi:10.1021/acscentsci.1c01603